InvestorsHub Logo
Followers 15
Posts 1647
Boards Moderated 0
Alias Born 05/15/2015

Re: None

Monday, 04/03/2017 7:34:48 PM

Monday, April 03, 2017 7:34:48 PM

Post# of 91822
GOVX: Zika platform at CENTER of NIH $100M trials.


NOTE: The NIH news today concerning the HIV vax effort put GOVX in the top tier of HIV related bio/pharmas

The NIH is also placing a priority on the GOVX DNA based platform for the Zika vax trials that is now kicking into high gear.

My standing advice is to buy 500,000 shares of GOVX and sit back.

If it drops, buy more.


Here is the NIH Zika news:
http://hosted.ap.org/dynamic/stories/U/US_MED_ZIKA_VACCINE?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT&CTIME=2017-03-31-14-55-50


GeoVax: DNA based Zika vax:
http://www.fiercepharma.com/vaccines/geovax-breaks-into-zika-vaccine-realm-promising-preclinical-data

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.